Follicular Lymphoma Clinical Trials 2024

What are the top hospitals conducting follicular lymphoma research?

When it comes to advancing the treatment options for follicular lymphoma, several top hospitals are leading the charge. In Houston, M D Anderson Cancer Center stands out with its five ongoing clinical trials dedicated to this specific type of lymphoma. This renowned institution has an impressive track record, having conducted 25 trials focused on follicular lymphoma since their first recorded trial in 1998. Meanwhile, in Boston's esteemed Dana-Farber Cancer Institute, researchers are also making significant contributions with five active follicular lymphoma trials and a history of 13 completed studies dating back to their inaugural trial in 2004.

Notably joining these institutions is The University of Texas MD Anderson Cancer Center, which operates independently from the main M D Anderson facility in Houston; they currently have four active clinical trials addressing follicular lymphoma while having achieved seven prior investigations starting only as recently as2013. Another notable location contributing significantly to research efforts is Ohio State University Comprehensive Cancer Center located at Columbus where three current clinical experiments revolve around Follicular Lymphomas.They have nearly a decade-long successful effort with twenty previous investigative undertakings initiated back during2010 that already contributes towards understanding ever-elusive cancer.

These hospitals serve as beacons of hope for patients diagnosed with follicular lymphoma by pushing boundaries and searching for innovative treatments. By conducting these trials and dedicating resources to furthering our understanding of this complex disease, they bring us closer to improved outcomes and potentially life-saving breakthroughs.

Which are the best cities for follicular lymphoma clinical trials?

When it comes to follicular lymphoma clinical trials, several cities stand out as leaders in research and development. Houston, Texas leads the pack with 20 active trials investigating treatments like Lenalidomide, Rituximab, and DRL_RI. New york, New York follows closely behind with 19 ongoing studies focused on innovative approaches such as Epcoritamab and Tazemetostat + R2 arm. Dallas, Texas is also a significant hub for clinical trials with 18 active studies exploring treatments like PF-06821497 and ibrutinib. These cities offer individuals with follicular lymphoma access to cutting-edge clinical trials that can potentially revolutionize treatment options and improve patient outcomes.

Which are the top treatments for follicular lymphoma being explored in clinical trials?

Follicular lymphoma, a challenging disease to tackle, is currently the focus of several groundbreaking clinical trials exploring new treatment options. Among the frontrunners in these trials are:

• Obinutuzumab: Engaging in four active trials and boasting 35 all-time follicular lymphoma trials since its introduction in 2009.
• Rituximab: Also involved in four ongoing trials, this well-established treatment has an impressive record with 102 all-time follicular lymphoma trials since being listed in 2000.
• Mosunetuzumab: With three active trials and ten all-time follicular lymphoma studies under its belt, this newly introduced therapy from 2021 shows promise.
• Lenalidomide: Engaged in three current follicular lymphoma trial endeavors and having participated in a total of 35 over time since its listing back in 2008.
• Epcoritamab: Though relatively recent on the scene (first listed just last year), it is already taking part actively in two clinical trials for follicular lymphoma alongside four others that have occurred thus far. These treatments offer hope for patients battling this complex condition, bringing us closer to finding effective solutions.

What are the most recent clinical trials for follicular lymphoma?

The field of follicular lymphoma research is advancing rapidly, with several recent clinical trials offering hope for improved treatment options. Among these trials is the investigation into subcutaneous Mosunetuzumab and oral Tazemetostat, a Phase 2 study that commenced on 9/1/2023. Additionally, there is a Phase 2 trial exploring Obinutuzumab + Glofitamab as a potential therapy for Marginal Zone Lymphoma in patients with follicular lymphoma (7/18/2023). Another promising avenue being explored is the combination of Epcoritamab and Rituximab in a Phase 2 trial (6/21/2023). Furthermore, researchers are actively evaluating dose escalation strategies through their Phase 1 and Phase 2 studies (5/19/2023), along with the benefits of ABBV-319 in another ongoing Phase 1 trial (4/26//2023). These innovative clinical trials offer renewed optimism for individuals battling follicular lymphoma.

What follicular lymphoma clinical trials were recently completed?

Recently completed clinical trials for follicular lymphoma have yielded valuable insights in the pursuit of improved treatments. In September 2021, the University of Chicago concluded a trial evaluating CC-486 as a potential therapy option. Other notable completed trials include Obinutuzumab, sponsored by Hoffmann-La Roche and finished in February 2019; AMG 562, sponsored by Amgen and completed in October 2018; TRPH-222, sponsored by Triphase Research and Development III Corp., also accomplished in October 2018. These advancements bolster our understanding of follicular lymphoma management approaches and bring us closer to more effective treatment strategies for patients facing this challenging disease.